Evidence map›Paper›PMID 32860262›Full record

Trial reportTransfusion2020

Recently acquired infection among HIV-seropositive donors in the US from 2010-2018.

Claire Quiner, Roberta Bruhn, Eduard Grebe, Clara Di Germanio, Debra Kessler, Rita Reik, Phillip Williamson, Dylan Hampton, Rahima Fayed, Steve A Anderson and 6 more

Open access · greenAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Claire QuinerVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0003-4419-1542
Roberta BruhnVitalant Research Institute, San Francisco, California, USA.
Eduard GrebeVitalant Research Institute, San Francisco, California, USA.
Clara Di GermanioVitalant Research Institute, San Francisco, California, USA.
Debra KesslerNew York Blood Center, New York, New York, USA.
Rita ReikOneBlood, St. Petersburg, Florida, USA.
Phillip WilliamsonCreative Testing Solutions, Tempe, Arizona, USA.
Dylan HamptonVitalant Research Institute, San Francisco, California, USA.
Rahima FayedAmerican Red Cross Scientific Affairs, Gaithersburg, Maryland, USA.
Steve A AndersonU.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Alan E WilliamsU.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Simone A GlynnNational Heart, Lung and Blood Institute, National Institutes of Health, Rockville, Maryland, USA.
Michael P BuschVitalant Research Institute, San Francisco, California, USA.
Susan L StramerAmerican Red Cross Scientific Affairs, Gaithersburg, Maryland, USA.ORCID 0000-0002-5865-6366
Brian CusterVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-6251-366X
Transfusion-Transmissible Infections Monitoring System (TTIMS)
Pacific Research Institute · USUniversity of California, San Francisco · USAmerican Red Cross · USUnited States Food and Drug Administration · USNational Institutes of Health · USNew York Blood Center · USOneBlood · US

Funding

FDA HHS HHSF223201510149CFDA HHS HHSF223201510165C
6 · The paper itself

Abstract

backgroundMonitoring of transfusion-transmissible infections in the blood supply is essential for blood safety, as the donor population is not static, and changes in policy, donor behavior, or other factors could increase the risk of recipient infection. We assessed patterns of recently acquired HIV infection in US blood donors, including before and after the implementation of the 12-month deferral for men who have sex with men (MSM). STUDY DESIGN AND

methodsA large convenience sample of donations from donors testing HIV-1 nucleic acid testing (NAT) and serology-reactive were further tested with the Sedia HIV-1 Limiting Antigen enzyme immunoassay. Samples were analyzed across available demographic and donation data to provide an assessment of recently acquired HIV infection in US blood donors from 2010 to 2018.

resultsOverall, 317 of 1154 (27.5%; 95% confidence interval, 24.9%-30.1%) donations from HIV NAT and serology-reactive donors had recently acquired HIV infection. There was no evidence of change in the percentages of recent HIV infection by year over the study period, either in all donors or in male donors, including after the MSM policy change. In multivariable logistic regression analysis, donors aged 24 years or younger were over 2.7 times more likely and repeat donors 2.2 times more likely to have recently acquired HIV infection compared to donors aged 55 years or older and first-time donors, respectively.

conclusionPatterns of recently acquired HIV infection varied by demographics but not over time. These findings suggest no impact of the MSM policy change on recently acquired HIV infection in US blood donors.

Indexed as

Blood DonorsBlood SafetyDonor SelectionHIV-1HIV InfectionsSexual and Gender MinoritiesAdolescentAdultFemaleHumansMaleMiddle AgedUnited States

Identifiers

PMID32860262
PMCPMC11630110
OpenAlexW3082750617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.